At a glance

ClinicalIndex Comparison Record

N/ACompleted· 4,680 enrolled

Drug / intervention

Peginterferon alfa-2a (Pegasys®)drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01070550

NCT01070550N/ACompleted

Compare CT.gov

Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons.

Hoffmann-La Roche·observational·Posted Feb 18, 2010·Updated Jun 15, 2016

In Brief

An observational study evaluating Peginterferon alfa-2a (Pegasys®) for Hepatitis C, Chronic. Completed, enrolled 4,680 participants across 266 sites in 14 countries.

Detailed Summary

This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is \<5000.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsHepatitis C, Chronic

CountriesAustria, Brazil, Canada, Croatia, France, Hungary, Mexico, Morocco, North Macedonia, Poland, Romania, Serbia, Slovenia, Sweden

Collaborators--

Timeline

N/ACompletedFinished

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJun 2007

First PostedFeb 2010

Primary CompletionJul 2011

TodayJul 2026

First PostedFeb 18, 2010

Enrollment StartJun 1, 2007

Primary CompletionJul 1, 2011

TodayJul 2, 2026

Enrollment to primary: 4.1 yearsPosted 16.4 years ago

Interventions

Peginterferon alfa-2a (Pegasys®)drug

Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.